Last reviewed · How we verify
LY686017
At a glance
| Generic name | LY686017 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use (PHASE3)
- Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis
- Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis (PHASE3)
- Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis (PHASE2)
- Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis (PHASE2)
- Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2) (PHASE3)
- Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE) (PHASE3)
- Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY686017 CI brief — competitive landscape report
- LY686017 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI